Moderna signs $35 million deal with cancer drug developer CytomX
Reuters
Published Jan 05, 2023 04:39PM ET
Updated Jan 05, 2023 06:00PM ET
(Reuters) - Moderna (NASDAQ:MRNA) Inc on Thursday announced a $35 million licensing deal with cancer-focused drug developer CytomX Therapeutics (NASDAQ:CTMX) to work on messenger RNA-based therapies for a wide range of diseases.
Shares of California-based CytomX rose more than 50% in extended trading.
The firm will get $5 million in prepaid research funding as part of the upfront payment and it is eligible for up to about $1.2 billion in future milestone payments, the companies said in a joint statement.
The news comes a month after an experimental cancer vaccine from Moderna based on mRNA technology was shown to work against a type of skin cancer.
The deal offers CytomX access to Moderna's mRNA technology, which has been used to develop COVID-19 vaccines, while Moderna would get access to CytomX's Probody platform, used in the development of cancer therapies targeting diseased tissues.
Moderna said it will also pay tiered royalties to CytomX on global sales of any products which enter the market under the deal. The agreement also provides the biotech company the option to participate in a future equity financing by CytomX.
The companies will work together to discover experimental therapies and Moderna will be responsible for human trials and commercial activities of products.
An mRNA-based therapy or vaccine works by instructing human cells to produce proteins that can spur the immune system into action.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.